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Abstract 
Review of histologic subtypes of mesothelioma, 
with associated clinical, pathologic, and molecular 
data. 
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Identity 
Malignant pleural mesothelioma (MPM) is a rare but 
aggressive cancer associated with median survival of 
7-13 months from diagnosis and limited effective 
treatment options (Beebe-Dimmer et al., 2016). 
MPM is classified by the World Health Organization 
into three major histologic subtypes: epithelioid, 
mixed/biphasic, and sarcomatoid (Galateau-Salle et 
al., 2016). The precise incidence of each type varies 
by study and sampling technique (biopsy versus 
surgical resection), but epithelioid is the most 
common, followed by biphasic and sarcomatoid 
respectively. Histologic subtype has significant 
implications for prognosis, with the poorest 
outcomes observed for sarcomatoid tumors. 
Clinics and pathology 
Etiology 
Over 80% of MPM cases are associated with 
asbestos exposure, and therefore asbestos is the 
major factor implicated in MPM tumorigenesis 
(Broeckx and Pauwels, 2018). The mechanisms 
underlying asbestos-induced mutagenesis and 
alterations in gene expression are varied, and include 
generation of reactive oxidants, induction of chronic 
inflammation, and direct physical interference with 
mitotic structures (Huang et al., 2011). Beyond 
asbestos exposure, known causative factors of MPM 
include exposure to other non-asbestos fibres, 
radiation exposure (such as therapeutic radiation and 
Thorotrast), other chronic mesothelial inflammatory 
conditions, and certain germline mutations 
particularly in BRCA1-associated protein 1 (BAP1) 
(Attanoos et al., 2018). However, these constitute a 
small percentage of cases. The majority of non-
asbestos associated MPM are considered idiopathic 
(Attanoos et al., 2018). 
Epidemiology 
Approximately 3000 new patients in the United 
States are diagnosed with MPM every year (Beebe-
Dimmer et al., 2016). The latency period between 
asbestos exposure and diagnosis of MPM ranges 
from 20-40 years. As a result, over 2/3 of MPM is 
diagnosed in patients over age 65. Males are affected 
approximately four times as commonly as females 
corresponding to patterns in occupational exposure. 
Use of asbestos has been banned in the United States 
since the 1970s, when the EPA's Clean Air Act 
(1973) banned most spray-applied asbestos products 
for insulation. In 1989, the EPA enacted the 
Asbestos Ban and Phase Out Rule which aimed to 
impose a complete ban on the importation, 
production, and sale of asbestos-containing 
products. However, due to the long latency period 
and ongoing use in the developing world, the 
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incidence of MPM is estimated to increase over the 
next several decades (Tolani et al., 2018, Cinausero 
et al., 2019). 
Clinics 
MPM does not become symptomatic until it is 
advanced. Symptoms include dyspnoea, chest pain, 
and cough. MPM has a median overall survival of 7-
13 months from the time of diagnosis with 5-year 
survival of less than 10%, although patients who are 
treated with multimodality therapy have shown 
median survival of 13-23.9 months (Beebe-Dimmer 
et al., 2016, Zhuo et al., 2019, Cao et al. 2010). 
Longer survival is associated with female sex, 
younger age at diagnosis, earlier clinical stage, 
absent lymph node involvement, and lower 
comorbidity score (Van Gerwen et al., 2019). 
Beyond the TNM staging system, clinical factors 
associated with shorter survival include increased 
tumor volume and maximal interlobar thickness as 
measured on computed tomography, elevated serum 
lactate dehydrogenase, neutrophil-to-lymphocyte 
ratio >5, anemia, and malnutrition (Gill et al., 2018; 
Doi et al., 2019; Harris et al., 2019). Histologic 
subtype is one of the most significant prognostic 
factors, and non-epithelioid MPM is associated with 
shorter survival than epithelioid MPM (hazard Ratio 
(HR) 1.3; p<0.001; Flores et al., 2008). 
Pathology 
Histologic subtype is defined by tumor cell 
morphology. Epithelioid tumors are ≥ 90% 
epithelioid-shaped cells, sarcomatoid tumors are ≥ 
90% spindle-shaped cells, and biphasic tumors are a 
combination of the two in varying proportions. 
While epithelioid is consistently the most prevalent 
histologic subtype of MPM, the relative incidence of 
each subtype varies by study population and by 
specimen type. An estimate by Suzuki et al (2001) 
identified an overall prevalence of 61.5%, 22%, and 
16.4% for epithelioid, biphasic, and sarcomatoid, 
respectively. More recently, Chirieac and colleagues 
(2019) compared subtypes as identified by biopsy 
versus surgical resection and found 80.6% 
concordance. Sarcomatoid histology on biopsy was 
found to have the highest correlation with resection 
histology, followed by biphasic and epithelioid.  
Histologic subtype is a significant independent 
prognostic factor, and each subtype carries unique 
features. For all three subtypes, the degree of 
differentiation correlates with survival. Poorly 
differentiated tumors have a HR of 2.5 compared 
with well or moderately differentiated tumors (Zhuo 
et al., 2019).  
Epithelioid - This subtype is the most common and 
associated with most favourable prognosis (median 
survival 14.4 months, Verma et al., 2018). The 
epithelioid subtype can exhibit a range of 
morphologies, including solid (the most prevalent, 
44%), tubulopapillary (29%), micropapillary (13%), 
tubular (7%), and trabecular (2%). Most epithelioid 
MPM contains more than one growth pattern. The 
solid type in particular is associated with high-grade 
nuclear features as well as shorter median overall 
survival, while tubulopapillary and micropapillary 
have the longest overall survival (Krasinskas et al., 
2016).  
In addition to growth pattern, nuclear grade, mitotic 
count, and necrosis have been found to predict 
survival in epithelioid MPM (Rosen et al., 2018). 
Higher Ki67 corresponds with shorter median 
overall survival in epithelioid, but not in non-
epithelioid MPM. Ki67 level also decreases 
following chemotherapy, which is consistent with 
the prognostic effect of treatment in this group 
(Ghanim et al., 2015).  
Patients with epithelioid MPM were found to benefit 
independently from both surgery and chemotherapy 
(Verma et al., 2018). Poor surgical candidates with 
epithelioid histology and minimal pleural disease 
can in rare cases be observed prior to resorting to 
chemotherapy (Kindler et al., 2018).  
Biphasic - Current WHO criteria for defining 
biphasic tumors require a mixture of epithelial and 
spindle-shaped cells, with at least 10% of cells 
matching each type. However, the relative 
proportion of each cell type within biphasic tumors 
has implications for clinical behaviour. An analysis 
by Vigneswaran and colleagues (2017) 
demonstrated that the amount of epithelioid 
differentiation in biphasic MPM is a significant 
predictor of survival. Similarly, Harling and 
colleagues (2019) demonstrated shorter survival 
associated with increased sarcomatoid component in 
biphasic tumors.  
Diagnosing biphasic MPM can be challenging on the 
basis of morphology alone. In one review series, 
17% of cases originally diagnosed as biphasic were 
reclassified as pure epithelioid and 12% as pure 
sarcomatoid. Only 23% of biphasic diagnoses were 
made with morphology or immunohistochemistry 
(IHC) alone, with the remaining 77% requiring 
additional IHC assessment to confirm diagnosis 
(Galateau-Salle et al., 2018).  
Biphasic tumors are sometimes grouped with 
sarcomatoid as 'non-epithelioid' based on their 
clinical behaviour. For example, atypical mitoses are 
associated with decreased survival in non-epithelioid 
mesothelioma, but, unlike in epithelioid MPM, 
mitotic count, necrosis, and nuclear atypia are not 
associated with survival (Habougit et al., 2017). On 
imaging, non-epithelioid MPM is more frequently 
associated with calcified plaques (Escalon et al., 
2018). Galateau-Salle and colleagues (2018) 
demonstrated the presence of a transitional 
phenotype was associated with significantly shorter 
survival compared to biphasic tumors without 
transitional elements and behave in a manner 
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prognostically similar to pure sarcomatoid tumors. 
PD-L1 expression has also been found to be higher 
in both biphasic and sarcomatoid than in epithelioid 
MPM (Brosseau et al., 2019).  
However, there are meaningful distinctions between 
biphasic and pure sarcomatoid MPM. Patients with 
biphasic tumors have an intermediate overall 
survival compared to epithelioid and sarcomatoid 
(median 9.5 months, Verma et al., 2018). Treatment 
with pleurectomy/decortication, radiotherapy, or 
chemotherapy improves survival compared with 
supportive care in this group but not sarcomatoid 
tumors, with selective benefit of radiotherapy in 
tumors with higher sarcomatoid proportion (Verma 
et al., 2018, Harling et al., 2019).  
Sarcomatoid - Additional characteristics for 
diagnosis of the sarcomatoid subtype, in addition to 
the presence of ≥ 90% spindle-shaped cells, include 
high nuclear/cytoplasmic ratio and frank 
sarcomatoid features (Dacic et al., 2019). It can 
sometimes be histologically difficult to distinguish 
sarcomatoid MPM from benign conditions such as 
fibrous pleuritis; Kinoshita and colleagues (2018) 
demonstrated that the incorporation of IHC is highly 
specific in distinguishing these conditions.  
Sarcomatoid histology is associated with larger 
tumor size at diagnosis and more advanced TNM 
stage (Paajanen et al., 2018). Patients with 
sarcomatoid tumors have the lowest median overall 
survival of the three subtypes (median 5.3 months, 
Verma et al., 2018). Gross macroscopic resection 
does not significantly prolong survival in 
sarcomatoid tumors, in contrast to epithelioid and 
biphasic tumors (Verma et al., 2018). These patients 
have a diminished response to systemic 
chemotherapy (Kindler et al., 2018, Mansfield et al., 
2014).  
Recent guidelines have recommended that 
sarcomatoid tumors (along with biphasic) should be 
considered candidates for systemic therapy and 
should not be excluded from first-line clinical trials 
on the basis of histology alone (Nicholson et al., 
2019). 
 
Figure 1 Malignant pleural mesothelioma, epithelioid type. 
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Figure 3 Malignant pleural mesothelioma, sarcomatoid type. 
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Treatment 
Multimodal therapy is the standard approach to 
MPM. The majority of patients are not candidates for 
surgery at presentation due to advanced disease, age, 
or comorbidities (Sugarbaker et al., 2014). For these 
patients, platinum-based chemotherapy  
(cisplatin plus pemetrexed) is first line treatment 
(Cinausero et al., 2018). In patients with resectable 
disease, the goal of surgery is macroscopic complete 
resection. This can be accomplished via lung-sparing 
surgery (extended pleurectomy and decortication) or 
extrapleural pneumonectomy (Friedberg et al., 
2019). Lung-sparing techniques have increased in 
favour due to lower morbidity and comparable 
outcomes. However, five-year survival following 
radical surgery remains low at approximately 15% 
(Cinausero et al., 2019). Radiation therapy also plays 
a role in select patients. There is some evidence that 
the addition of antiangiogenic agents such as 
bevacizumab can improve outcomes in combination 
with chemotherapy (Zalcman et al., 2016). Given 
their success in other solid tumors, targeted therapies 
and immunotherapeutics are being actively explored 
in MPM with mixed results (Cinausero et al., 2019). 
Overall, a review of 20,561 MPM patients in the 
National Cancer Database by Nelson and colleagues 
(2017) identified significant improvement in patient 
survival with surgery-based multimodality therapy 
compared with surgery alone, with the strongest 
effect seen using a combination of cancer-directed 
surgery, chemotherapy, and radiation therapy (HR 
0.52). 
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